Immunocore reports fourth quarter and full year 2024 financial results and provides a business update
Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025Executing on ...
The Lancet8h
Trastuzumab rezetecan, a new antibody–drug conjugate in HER2-mutated NSCLC
HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...